^
CANCER:

Astrocytoma





Show legend
Group by Gene:
Include preclinical:

0
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
1
DNA synthesis inhibitor
cisplatin
temozolomide
2
Tubulin polymerization promoter
carboplatin
3
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
4
Topoisomerase II inhibitor
etoposide IV
5
Alkylating agent
lomustine
6
VEGF-A inhibitor
bevacizumab
7
mTOR inhibitor
everolimus
8
Alkylating agent, Tubulin polymerization inhibitor
lomustine + procarbazine hydrochloride + vincristine liposomal
9
MEK1 inhibitor
cobimetinib
10
Tubulin polymerization promoter, Tubulin polymerization inhibitor
carboplatin + vincristine
11
BRAF inhibitor
dabrafenib
PLX4720
12
FGFR inhibitor
pemigatinib
ABSK091
13
MEK inhibitor
selumetinib
trametinib
14
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
15
PD1 inhibitor
nivolumab
16
EGFR inhibitor, EGFRvIII inhibitor
WSD0922
17
mTOR inhibitor, BRAF inhibitor, BRAF V600E inhibitor
vemurafenib + everolimus
18
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
19
Chemotherapy
PCV
20
Alkylating agent, DNA synthesis inhibitor
carmustine
temozolomide gel
21
BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
vemurafenib + cobimetinib
22
Topoisomerase II inhibitor, DNA synthesis inhibitor
cisplatin + etoposide IV
23
DNA synthesis inhibitor, Chemotherapy
PCV + thioguanine
24
IDH2 inhibitor, IDH1 inhibitor
S95032
25
PD-L1 inhibitor, MEK1 inhibitor
atezolizumab + cobimetinib
26
Tubulin polymerization promoter, Tubulin polymerization inhibitor, DNA synthesis inhibitor
carboplatin + temozolomide + vincristine
27
CDK4 inhibitor, BRAF inhibitor, CDK6 inhibitor
palbociclib + PLX4720
28
CDK4 inhibitor, CDK6 inhibitor
palbociclib
No biomarker
IDH2 mutation
IDH2 mutation + NTRK3 fusion
BRAF V600E
BRAF V600
BRAF mutation
IDH2 mutation + NTRK1 fusion
IDH2 mutation + BRAF V600E
IDH2 mutation + NTRK2 fusion
IDH1 mutation + BRAF V600E
IDH1 mutation + NTRK3 fusion
IDH1 mutation + NTRK2 fusion
IDH1 mutation + NTRK1 fusion
IDH1 R132H
IDH1 mutation
MGMT promoter methylation
FGFR fusion
FGFR mutation
FGFR3-TACC3 fusion
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion
BRAF V600E + PIK3CA mutation
ABCB1 G412G
EGFRvIII mutation
NACC2-NTRK2 fusion
TMB-H
KIAA1549-BRAF fusion
NRAS mutation
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation